250 related articles for article (PubMed ID: 28655089)
1. [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients].
Lu J; Du J; Fu WJ; He HY; Li L; Li R; Zhou LL; Jiang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):475-479. PubMed ID: 28655089
[No Abstract] [Full Text] [Related]
2. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
[TBL] [Abstract][Full Text] [Related]
3. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
Lu J; Lu J; Liu A; Fu W; Du J; Huang X; Chen W; Hou J
Biomed Res Int; 2015; 2015():856704. PubMed ID: 26640799
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Cho H; Yoon DH; Lee JB; Kim SY; Moon JH; Do YR; Lee JH; Park Y; Lee HS; Eom HS; Shin HJ; Min CK; Kim JS; Jo JC; Kang HJ; Mun YC; Lee WS; Lee JJ; Suh C; Kim K;
Am J Hematol; 2017 Dec; 92(12):1280-1286. PubMed ID: 28833417
[TBL] [Abstract][Full Text] [Related]
5. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K; Wellard C; Moore E; McQuilten Z; Blacklock H; Harrison SJ; Ho PJ; King T; Quach H; Mollee P; Walker P; Wood E; Spencer A;
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e510-e520. PubMed ID: 33785297
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
7. Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society.
Abe Y; Sunami K; Yamashita T; Ueda M; Takamatsu H; Narita K; Kobayashi H; Kitadate A; Takeuchi M; Matsue K
Oncotarget; 2019 Jan; 10(5):595-605. PubMed ID: 30728910
[TBL] [Abstract][Full Text] [Related]
8. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
10. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma.
Du C; Li L; Fan H; Mao X; Liu J; Xu Y; Sui W; Deng S; Li C; Zhao J; Yi S; Hao M; Zou D; Zhao Y; Qiu L; An G
Hematology; 2023 Dec; 28(1):2258686. PubMed ID: 37724573
[TBL] [Abstract][Full Text] [Related]
11. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and prognostic factors of induction therapy combined with autologous stem cell transplantation in 201 patients with multiple myeloma].
Jin L; Fu W; Xi H; Zhang C; Du J; He H; Jiang H; Zeng T; Fan J; Zhou L; Chang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):14-9. PubMed ID: 26876247
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
14. [Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma].
Deng SH; Xu Y; Sui WW; An G; Mao XH; Li ZJ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):487-493. PubMed ID: 28655091
[No Abstract] [Full Text] [Related]
15. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
[TBL] [Abstract][Full Text] [Related]
17. The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.
Chen H; Zhou N; Hu X; Wang D; Wei W; Peng R; Chen X; Shi H; Wu L; Yu W; Zhao W; Zhou F
Hematol Oncol; 2023 Feb; 41(1):139-146. PubMed ID: 36252280
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
19. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
[TBL] [Abstract][Full Text] [Related]
20. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]